Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | BRAF | P15056 | 2/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | RAF1 | P04049 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.69 |
| ▸ | SMO | Q99835 | 2/20 | 0.62 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891790 | 0.85 | MAPK14 (0.70) | MAPK14MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL5897054 | 0.84 | MAPK14 (0.65) | MAPK14MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL9609625 | 0.83 | KCNK3 (0.69) | MAPTKDM4EBRAFTP53KCNK3 | |
| SCHEMBL6484862 | 0.83 | MAPK14 (0.85) | MAPK14MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL10028403 | 0.83 | MAPK14 (0.85) | MAPK14MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL25069020 | 0.82 | MAPK14 (0.63) | MAPK14MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL6782029 | 0.82 | MAPK14 (0.76) | MAPK14MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL6781525 | 0.82 | MAPK14 (0.83) | MAPK14MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL6477991 | 0.82 | MAPK14 (0.76) | MAPK14MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL1424183 | 0.82 | MAPK14 (1.00) | MAPK14MAPTKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | MAPK14 146/4885MAPT 349/4885KDM4E 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.